PAG
BBC icon

Private Advisor Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Private Advisor Group’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,550
Closed -$110K – 1734
2020
Q2 		$110K Buy
+2,550
New +$97.6K ﹤0.01% 1650
2017
Q3 		– Sell
-9,200
Closed -$224K – 1467
2017
Q2 		$224K Buy
+9,200
New +$206K 0.01% 1210

Other funds holding BBC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FEM
Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Private Advisor Group's BBC Position: Q3 2020 in Review

Private Advisor Group sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2020, closing a stake of 2,550 shares — an estimated $110K sold.

Private Advisor Group first reported a position in BBC in Q2 2017 and held it in 2 quarters. The position peaked at $224K in Q2 2017. 18 funds tracked by Wall St. Rank hold BBC as of Q3 2020.

  • Private Advisor Group reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 2,550 Virtus Biotech Clinical Trials ETF shares in Q3 2020, an estimated $110K.
  • Private Advisor Group first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2017 and held it in 2 quarters.
  • Private Advisor Group's Virtus Biotech Clinical Trials ETF position peaked at $224K in Q2 2017.
  • 18 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.